Achievement of tolerance induction to prevent acute graft-vs.-host disease

Govindarajan Thangavelu, Bruce R Blazar

Research output: Contribution to journalReview article

Abstract

Acute graft-vs.-host disease (GVHD) limits the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), a main therapy to treat various hematological disorders. Despite rapid progress in understanding GVHD pathogenesis, broad immunosuppressive agents are most often used to prevent and remain the first line of therapy to treat GVHD. Strategies enhancing immune tolerance in allo-HSCT would permit reductions in immunosuppressant use and their associated undesirable side effects. In this review, we discuss the mechanisms responsible for GVHD and advancement in strategies to achieve immune balance and tolerance thereby avoiding GVHD and its complications.

Original languageEnglish (US)
Article number309
JournalFrontiers in immunology
Volume10
Issue numberMAR
DOIs
StatePublished - Jan 1 2019

Fingerprint

Immune Tolerance
Hematopoietic Stem Cell Transplantation
Immunosuppressive Agents
Transplants
Therapeutics

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Alpha-1 antitrypsin
  • Graft-vs.-host disease
  • Immune tolerance
  • T regulatory cells

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

Achievement of tolerance induction to prevent acute graft-vs.-host disease. / Thangavelu, Govindarajan; Blazar, Bruce R.

In: Frontiers in immunology, Vol. 10, No. MAR, 309, 01.01.2019.

Research output: Contribution to journalReview article

@article{87f14a483be7494ea24b5769de0e0dd2,
title = "Achievement of tolerance induction to prevent acute graft-vs.-host disease",
abstract = "Acute graft-vs.-host disease (GVHD) limits the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), a main therapy to treat various hematological disorders. Despite rapid progress in understanding GVHD pathogenesis, broad immunosuppressive agents are most often used to prevent and remain the first line of therapy to treat GVHD. Strategies enhancing immune tolerance in allo-HSCT would permit reductions in immunosuppressant use and their associated undesirable side effects. In this review, we discuss the mechanisms responsible for GVHD and advancement in strategies to achieve immune balance and tolerance thereby avoiding GVHD and its complications.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Alpha-1 antitrypsin, Graft-vs.-host disease, Immune tolerance, T regulatory cells",
author = "Govindarajan Thangavelu and Blazar, {Bruce R}",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fimmu.2019.00309",
language = "English (US)",
volume = "10",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - Achievement of tolerance induction to prevent acute graft-vs.-host disease

AU - Thangavelu, Govindarajan

AU - Blazar, Bruce R

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Acute graft-vs.-host disease (GVHD) limits the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), a main therapy to treat various hematological disorders. Despite rapid progress in understanding GVHD pathogenesis, broad immunosuppressive agents are most often used to prevent and remain the first line of therapy to treat GVHD. Strategies enhancing immune tolerance in allo-HSCT would permit reductions in immunosuppressant use and their associated undesirable side effects. In this review, we discuss the mechanisms responsible for GVHD and advancement in strategies to achieve immune balance and tolerance thereby avoiding GVHD and its complications.

AB - Acute graft-vs.-host disease (GVHD) limits the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), a main therapy to treat various hematological disorders. Despite rapid progress in understanding GVHD pathogenesis, broad immunosuppressive agents are most often used to prevent and remain the first line of therapy to treat GVHD. Strategies enhancing immune tolerance in allo-HSCT would permit reductions in immunosuppressant use and their associated undesirable side effects. In this review, we discuss the mechanisms responsible for GVHD and advancement in strategies to achieve immune balance and tolerance thereby avoiding GVHD and its complications.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Alpha-1 antitrypsin

KW - Graft-vs.-host disease

KW - Immune tolerance

KW - T regulatory cells

UR - http://www.scopus.com/inward/record.url?scp=85063712437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063712437&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2019.00309

DO - 10.3389/fimmu.2019.00309

M3 - Review article

VL - 10

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - MAR

M1 - 309

ER -